kynurenic acid has been researched along with Anxiety in 14 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adults with chronic kidney disease (CKD) exhibit alterations in tryptophan metabolism, mainly via the kynurenine pathway, due to higher enzymatic activity induced mainly by inflammation." | 7.83 | Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study. ( Davies, N; Hilder, EF; Jose, MD; Karu, N; McKercher, C; Nichols, DS; Shellie, RA, 2016) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| "Adults with chronic kidney disease (CKD) exhibit alterations in tryptophan metabolism, mainly via the kynurenine pathway, due to higher enzymatic activity induced mainly by inflammation." | 3.83 | Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study. ( Davies, N; Hilder, EF; Jose, MD; Karu, N; McKercher, C; Nichols, DS; Shellie, RA, 2016) |
| "), an endogenous neuroactive metabolite of tryptophan, attenuated the most stable effect of anxiogens in this model of anxiety--a decrease in the rate of leanings-out of the dark compartment --induced by caffeine, pentylenetetrazole and yohimbine, but not by beta-phenylethylamine (PEA)." | 3.70 | Antagonism of kynurenic acid to anxiogens in mice. ( Lapin, IP, 1998) |
| "To investigate if blockade of the modulatory glycine site of NMDA receptors in the dorsal periaqueductal grey (DPAG) would produce anxiolytic effects, groups of 9-14 rats received microinjections into this structure of 7-chloro-kynurenic acid (7-Cl-KY, 4 and 8 nmol) or 3-amino-1-hydroxypyrrolid-2-one (HA-966, 30 or 100 nmol), two selective antagonists at the strychnine-insensitive glycine modulatory site, and were submitted to the elevated plus-maze, an ethologically based animal model of anxiety." | 3.69 | Anxiolytic effect of glycine antagonists microinjected into the dorsal periaqueductal grey. ( Carobrez, AP; Graeff, FG; Guimarães, FS; Matheus, MG; Nogueira, RL, 1994) |
| " In contrast, the anxiolytic effects of L-701,324 and reversal of these effects by glycine were unaffected by acute treatment with imipramine, chronic administration with placebo or the neuroleptic chlorpromazine, or sham ECS." | 1.31 | Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence. ( Nowak, G; Popik, P; Wróbel, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kimmel, M | 1 |
| Jin, W | 1 |
| Xia, K | 1 |
| Lun, K | 1 |
| Azcarate-Peril, A | 1 |
| Plantinga, A | 1 |
| Wu, M | 1 |
| Ataei, S | 1 |
| Rackers, H | 1 |
| Carroll, I | 1 |
| Meltzer-Brody, S | 1 |
| Fransson, E | 1 |
| Knickmeyer, R | 1 |
| Kucukkarapinar, M | 1 |
| Yay-Pence, A | 1 |
| Yildiz, Y | 1 |
| Buyukkoruk, M | 1 |
| Yaz-Aydin, G | 1 |
| Deveci-Bulut, TS | 1 |
| Gulbahar, O | 1 |
| Senol, E | 1 |
| Candansayar, S | 1 |
| Herrstedt, A | 1 |
| Bay, ML | 1 |
| Simonsen, C | 1 |
| Sundberg, A | 1 |
| Egeland, C | 1 |
| Thorsen-Streit, S | 1 |
| Djurhuus, SS | 1 |
| Magne Ueland, P | 1 |
| Midttun, Ø | 1 |
| Pedersen, BK | 1 |
| Bo Svendsen, L | 1 |
| de Heer, P | 1 |
| Christensen, JF | 1 |
| Hojman, P | 1 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 1 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Chrétien, F | 1 |
| Gaillard, R | 1 |
| Karu, N | 1 |
| McKercher, C | 1 |
| Nichols, DS | 1 |
| Davies, N | 1 |
| Shellie, RA | 1 |
| Hilder, EF | 1 |
| Jose, MD | 1 |
| Coppola, A | 1 |
| Wenner, BR | 1 |
| Ilkayeva, O | 1 |
| Stevens, RD | 1 |
| Maggioni, M | 1 |
| Slotkin, TA | 1 |
| Levin, ED | 1 |
| Newgard, CB | 1 |
| Ren, WH | 1 |
| Guo, JD | 1 |
| Cao, H | 1 |
| Wang, H | 1 |
| Wang, PF | 1 |
| Sha, H | 1 |
| Ji, RR | 1 |
| Zhao, ZQ | 1 |
| Zhang, YQ | 1 |
| Santos, P | 1 |
| Bittencourt, AS | 1 |
| Schenberg, LC | 2 |
| Carobrez, AP | 3 |
| Matheus, MG | 1 |
| Nogueira, RL | 1 |
| Graeff, FG | 2 |
| Guimarães, FS | 1 |
| Plaznik, A | 1 |
| Palejko, W | 1 |
| Nazar, M | 1 |
| Jessa, M | 1 |
| De Souza, MM | 1 |
| de Pádua Carobrez, A | 1 |
| Lapin, IP | 1 |
| Popik, P | 1 |
| Wróbel, M | 1 |
| Nowak, G | 1 |
| Schmitt, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for kynurenic acid and Anxiety
| Article | Year |
|---|---|
Exercise-mediated improvement of depression in patients with gastro-esophageal junction cancer is linked to kynurenine metabolism.
Topics: Aged; Anxiety; Depression; Exercise; Female; Humans; Inflammation; Kynurenic Acid; Kynurenine; Male; | 2019 |
13 other studies available for kynurenic acid and Anxiety
| Article | Year |
|---|---|
Metabolite trajectories across the perinatal period and mental health: A preliminary study of tryptophan-related metabolites, bile acids and microbial composition.
Topics: Adult; Anxiety; Bile Acids and Salts; Chromatography, Liquid; Depression; Dietary Fiber; Fatty Acids | 2022 |
Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress.
Topics: Anxiety; Biomarkers; COVID-19; Depression; Humans; Kynurenic Acid; Kynurenine; Survivors; Tryptophan | 2022 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study.
Topics: Aged; Aged, 80 and over; Anxiety; Biomarkers; Cognition; Cross-Sectional Studies; Depression; Female | 2016 |
Branched-chain amino acids alter neurobehavioral function in rats.
Topics: Amino Acids, Branched-Chain; Animals; Anxiety; Behavior, Animal; Brain; Diet; Diet, High-Fat; Dietar | 2013 |
Is endogenous D-serine in the rostral anterior cingulate cortex necessary for pain-related negative affect?
Topics: Animals; Anxiety; D-Amino-Acid Oxidase; Excitatory Amino Acid Antagonists; Fear; Glycine; Gyrus Cing | 2006 |
Elevated T-maze evaluation of anxiety and memory effects of NMDA/glycine-B site ligands injected into the dorsal periaqueductal gray matter and the superior colliculus of rats.
Topics: Animals; Anxiety; Glycine; Kynurenic Acid; Ligands; Male; Maze Learning; Memory; Microinjections; Pe | 2006 |
Anxiolytic effect of glycine antagonists microinjected into the dorsal periaqueductal grey.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Conditioning, Operant; Electric Stimulation | 1994 |
Effects of antagonists at the NMDA receptor complex in two models of anxiety.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anxiety; Behavior, Animal; Conflict, Psychological; Diazepam; | 1994 |
NMDA-coupled periaqueductal gray glycine receptors modulate anxioselective drug effects on plus-maze performance.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Binding, Competitive; Central Nervous System Stimulants; Diaz | 1998 |
Antagonism of kynurenic acid to anxiogens in mice.
Topics: Animals; Anxiety; Brain; Caffeine; Diazepam; Excitatory Amino Acid Antagonists; Injections, Intraper | 1998 |
Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Behavior, Animal; Chlordiazepoxide; Do | 2000 |
Anxiolytic effect of kynurenic acid microinjected into the dorsal periaqueductal gray matter of rats placed in the elevated plus-maze test.
Topics: Analysis of Variance; Animals; Anxiety; Exploratory Behavior; Kynurenic Acid; Male; Periaqueductal G | 1990 |